Introduction
Cardiovascular disease (CVD) is the leading cause of death in the industrialized world and has the highest disease burden for affected individuals when calculated as lifeyears lost [1] . The concentration of high-density lipoprotein cholesterol (HDL-C) has been shown to be inversely correlated to risk of CVD [2] and HDL is suggested to have atheroprotective effects by inducing cholesterol efflux from lipid-laden cells in the vascular wall and to reduce inflammatory, oxidative and thrombogenic signals [3, 4] . Today, there is a major need to find specific functions, protein or lipid compositions of HDL that are determinants of the anti-atherosclerotic capacity of HDL [5] .
Apolipoprotein A-I (apoA-I), the main structural protein of HDL, plays a key role in the genesis of HDL through its interaction with ATP-binding cassette A1 (ABCA1).
In this process, essentially lipid-free apoA-I acquires free cholesterol and phospholipids resulting in the formation of pre-beta HDL (disc-shaped nascent HDL).
As a cofactor of lecithin: cholesterol acyltransferase (LCAT), apoA-I is also essential for cholesteryl ester generation on HDL particles thereby directly affecting HDL maturation, i.e. the generation of larger spherical macromolecules [4] . In addition, apoA-I serves as a ligand for the binding of HDL to Scavenger Receptor Class B-1 (SR-B1) [6, 7] thereby mediating cellular cholesterol uptake in target organs like the liver and adrenals.
About 50 different mutations in apoA-I have been described, and of these over 20 have been linked to low levels of HDL-C in the circulation. In general, these mutations can be divided into two distinct groups, those that mostly reside within the N-terminal part of the protein and have been associated with amyloidosis and those residing within the central region and believed to affect the LCAT-activity [8] .
ApoA-I contains ten helical repeats that, during HDL formation, create a double belt structure with the hydrophobic amino acids towards the lipid center [9] . Helical repeats 6 to 7 and in particular Arg 173 , Arg 177 and Arg 184 [10] , and a protrusive loop in residues 183-204 [11] , are most likely crucial for the LCAT activation. Thus far only a few of the natural apoA-I mutations identified in humans have been described to be associated with altered/increased CVD risk. In addition, there is almost no information on the concentrations of e.g. the different apoA-I variants in plasma and how this may affect HDL genesis, function and composition.
Two mutations in the central region of full length (including signal and propeptide)
apoA-I that are associated with decreased apoA-I and HDL-C levels as well as an increased risk for CVD are apoA-I L202P (previously annotated as apoA-I L178P excluding signal-and pro-peptide) [12] and apoA-I K131del (previously annotated as apoA-I
K107del
, Marburg/Munster-2 variant and apoA-IHelsinki) [13, 14] . The new annotations follow the international guidelines for describing mutations in the human genome (http://www.hgvs.org/rec.html). The novel apoA-I L202P mutation was identified in six families and was associated with endothelial dysfunction and increased arterial wall thickness, a surrogate marker of CVD [12] . At that time, the mutant was not detected in plasma and it was assumed that the phenotypic effects were due to the half normal levels of wild-type apoA-I in the circulation of heterozygotes for this mutation. The apoA-I K131del mutation on the other hand was
shown to be present in Finnish kindred with high incidence of premature CVD but to have no effect on LCAT activity in vitro [14] . This mutation has also been found in a subject with intimal amyloidosis deposits combined with extensive atherosclerosis [15] . In the current study, we have investigated the presence of apoA-I L202P and apoA-I K131del variants in HDL of heterozygotes using improved MS analyses. In addition,
we analyzed their HDL protein profiles.
Materials and Methods

Chemicals
Endoproteinase Glu-C and 2,5-dihydroxybenzoic acid was purchased from SigmaAldrich (St. Louis, MO, US), IPG Dry strips were obtained from GE Healthcare (Little Chalfont, UK), Sypro Ruby stain was obtained from Bio-Rad (Hercules, CA, US), trypsin was purchased from Promega (Fitchburg, WI, US) and a standard peptide mixture for peptide mass fingerprinting was obtained from Applied Biosystems (Foster City, CA, US).
Study population
Three heterozygotes for the apoA-I L202P mutation were recruited from a study initially aimed at identifying genes that control HDL-C levels as described previously [12] .
Three subjects heterozygous for the apoA-I K131del mutation were identified by direct sequencing of the apoA-I gene in subjects with hypoalphalipoproteinemia. For both mutations, three age and gender matched family controls were included. Informed consent was obtained from all subjects for plasma sampling, storage, genetic and proteomic analysis, and vascular tests, under a protocol approved by the ethics committee of the Academic Medical Center in Amsterdam. Past medical history, presence of cardiovascular risk factors, use of medication, and information on geographic origin of the probands were assessed by questionnaires.
Isolation of HDL
Fasting blood was drawn (in EDTA containing tubes) from the subjects and centrifuged at 3000 g for 20 minutes. The plasma was separated and stored at -80°C until further analysis. HDL was isolated as previously described [16] . In short, plasma was mixed with 5% sucrose and 10 mg/mL EDTA and gently overlayered with a KBr/phosphate buffer solution (density 1.063 g/mL). Ultracentrifugation was performed at 290 000 g at 15˚C for 4 hours. HDL was collected from the middle of the tube and the fraction was mixed with a KBr/phosphate buffer (density 1.24 g/mL)
and a second round of ultracentrifugation was performed under the same conditions for 2h. HDL was collected from the top of the tubes and desalted. Protein concentration was measured with the Bio-Rad protein assay (Bio-Rad) and samples were lyophilized.
Two-dimensional gel electrophoresis (2-DE)
The 2-DE was performed as described earlier [16] . In short, lyophilized samples were reconstituted in a 2-DE sample solution [17] and 300 µg of total protein was isoelectrically focused in IPG Dry strip pH 3-10NL for 53 000 Vhrs. The second dimension was done by transferring the IPG strip to a homogenous 14% acrylamide gel on gel bond and running the electrophoresis overnight. Separated proteins were detected with Sypro Ruby and visualized with a Versadoc system (Bio-Rad) and
PDQuest software (Bio-Rad). Gel spots were matched and intensities were evaluated by relative densitometric quantification.
In gel digestion with Glu-C
Protein spots were visualized with a blue light transluminator (DR-180 B; Clara Chemical Research, Denver, CO, USA) and excised from the 2-DE gel. Excised gel pieces were washed with 50% acetonitrile/25 mM ammonium bicarbonate followed by 100% acetonitrile before being dried using a SpeedVac vacuum concentration system. Gel pieces were rehydrated with endoproteinase Glu-C (20µg/mL) in 25 mM ammonium bicarbonate and proteins were in-gel digested by incubating at 37˚C
overnight. The supernatant was transferred to a new tube while peptides were further extracted by incubation in 50% acetonitrile/5% TFA for 5 h on a shaker. Supernatants were pooled and dried by SpeedVac centrifugation. Dried peptides were reconstituted in 5 ul 0.1% TFA. formic acid in acetonitrile (solution B) and proteins were separated using a two-step gradient of 0% to 35% solution B during 27 minutes followed by a gradient to 100% solution B during 10 minutes. Capillary temperature and voltage were set to 250°C
MS analysis
and 150 V respectively with a gas flow of 6 L/min. Spectrum were obtained between m/z 100 and 1500 followed by automated online tandem MS by electron-transfer dissociation. Data was processed in DataAnalysis 3.4 (Bruker Daltronics).
Results
Identification of apoA-I L202P in HDL
In line with the previous report [12] , apoA-I L202P heterozygotes were characterized by an approximate 50 % reduction in plasma apoA-I levels and an approximate 60 % decrease of HDL-C compared with controls (Table I) . HDL was isolated from plasma, proteins were separated with 2-DE and apoA-I was further subjected to in-gel digestion. A substitution of leucine for proline does not result in a charge difference, and as a consequence, the apoA-I variant apoA-I L202P and wild-type A-I were expected to be located in the same spot on 2-DE gels in case the mutant was present in plasma HDL isolated through ultracentrifugation. To investigate if the mutated apoA-I form was present in plasma and for optimal detection of both wild-type and mutant peptide including residue 202, the samples were digested with the endoproteinase Glu-C that cleaves peptide bonds C-terminally of glutamic acid. The Essentially the same values (30.3%) were obtained when using ESI-Q-TOF MS as well as when peptides were separated by C18 reverse phase chromatography using nano-flow HPLC system and analyzed by electrospray ionization ion trap (29.8 %), further confirming our initial results. In addition, peak area determinations of a separate major peak (m/z 1252.7) from apoA-I, corresponding to a peptide not at the site of the mutation, showed very similar values between the wild-type individuals and heterozygotes (supplemental Table 1 ). In agreement with our results the ratio of the mutant peptide and this loading control peptide was also about 1/3 compared to the ratio of the wild-type peptide and this peptide in the heterozygotes (supplemental Table 1 ).
Analyses of apoA-I K131del in HDL
In contrast to carriers of the apoA-I L202P mutation, the heterozygotes for apoA-I
K131del
did not have lower apoA-I levels than controls (Table 1) . However, they did show a 30% reduction of HDL-C compared to controls. In line with a deletion of lysine, the 2-DE revealed a negative charge shift in the apoA-I isoform pattern with an additional acidic isoform in the heterozygotes that was not found in the controls (Figure 2 ).
ApoA-I was then subjected to in-gel digestion with Glu-C and analyzed by MALDI- corresponded to the mutant peptide VKAKVQPYLDDFQKWQEE ( Figure 3E ). In accordance with 2-DE pattern, the proportion of the mutant peptide was very different in the apoA-I isoforms. The most acidic isoform analyzed contained almost only the mutant peptide (>99%) and the proportion of the mutant gradually decreased with increased pI. The most basic isoform analyzed contained almost only the wild-type peptide (>95%). To estimate total relative abundance of the mutant and wild-type peptide, digests from all apoA-I isoforms were pooled and analyzed by MALDI-TOF MS. As illustrated in figure 3B and 3C, peak area ratio determinations (mutant peptide/wild-type peptide) showed that interestingly the mutant peptide was about 3-fold more abundant than the wild-type peptide in HDL from the heterozygotes (ranged from 200 to 480 %). The overall amounts of apoA-I in the analyses were about the same in heterozygotes and wild-type controls, as judged by peak area determinations of a major peak (m/z 1252.7) not at the site of the mutation (supplemental Table 1 ). In addition, the ratio of the mutant peptide and this loading control peptide was about 3 times the ratio of the wild-type peptide and the control peptide in the heterozygotes (supplemental Table 1 ).
Protein profiling of HDL from apoA-I L202P and apoA-I K131del heterozygotes
Analyses by 2-DE/MS showed alterations in the protein distribution patterns in HDL from the heterozygotes ( Table 2, supplemental Figure 2 and supplemental Table 2 ).
Besides less apoA-I, HDL of apoA-I L202P , heterozygotes contained less apoE and more zinc-α-2-glycoprotein than the controls. On the other hand, HDL of heterozygotes for the apoAI K131del mutation had increased distribution of α-1-antitrypsin and transthyretin.
We have previously reported that heterozygous carriers of the apoA-I L202P are characterized by low HDL-C, increased arterial wall thickness, endothelial dysfunction and a 24-fold increase in risk for CVD in heterozygotes compared to family controls [12] . Moreover, heterozygous carriers have reduced tissue cholesterol efflux [18] and their HDL appears to be functionally impaired with decreased antioxidant and anti-inflammatory potential [19] . In the initial study, apoA-I L202P was described not to be present in plasma of heterozygotes. The hypothesis that the mutated apoA-I was not expressed was strengthened by the observation of half normal levels of apoA-I in carriers [12] . In the current study, however, we have been able to clearly identify the mutated protein in HDL from the heterozygotes. By using Glu C instead of trypsin, larger peptides were obtained that facilitated the detection of the wild-type and the mutant peptide in the same sample. Our MS results also indicate that the mutated form of apoA-I is less abundant than the wild-type form and comprises approximately 25% of the total apoA-I in HDL. Leu 202 is located in -helix 7 and, in total, human native apoA-I contain ten helical repeats and ten prolines [20] .
Except for three prolines located N-terminally, the others separate seven of the helical repeats and are important for the correct bending of the apoA-I structure to allow the protein to bind the periphery of a spherical HDL particle [9] . Helices 7/8 do not contains an intermediate proline and experiments with mouse/human chimeric apoA-I indicate that introduction of a proline affects the binding of apoA-I to different sized HDL subclasses [21] . Therefore, it is tempting to speculate that replacement of Leu 202 with proline in -helix 7 may introduce an additional structural bend, which impairs the formation of native HDL. However, structural studies of apoA-I and HDL in relation to the mutation are needed to address whether this holds true.
Interestingly, the data obtained while studying apoA-I in carriers of the apoA-I
K131del
show very different results: In sharp contrast to apoA-I L202P , the apoA-I K131del was
shown not to affect total apoA-I in the circulation and was more abundant than wildtype apoA-I comprising about 75 % of total apoA-I in HDL of carriers. The relative abundance of the two different mutants and wild-type apoA-I was based on assessments of the mutant/wild-type peptide peak area ratios. In this respect, other factors that may affect the peak intensities should be considered such as the degree of ionization of wild-type and mutated peptides. However, substitution of a leucine with a proline would most likely create an increased signal [22] while loss of lysine a lower signal in MS. Since we observed the opposite, i.e. less of the mutated peptide than the wild-type peptide in the apoA-I L202P heterozygotes and more of the mutated peptide than the wild-type peptide in the apoA-I K131del heterozygotes, it is therefore more likely that we are underestimating the difference between the two mutations rather than overestimating it. By analyzing the two apoA-I variants separated with 2-DE, we also diminished possible bias caused by ion-suppression due to interference of other proteins in the analyses. In addition, essential the same results were obtained when normalizing the mutant peptide and wild-type peptide peak areas to the peak area of a major internal control peptide, not at the site of the mutation. Previously, a similar approach as we present in the current study has been applied to determine plasma ratio of wild-type/apoAI L159R (apoA-IFin) [23, 24] and to study myosin mutations in relation to cardiomyopathy [25] . Thus, differential quantitation of wildtype and mutant proteins with MS is an interesting new tool to study molecular and biochemical effects of mutations in heterozygotes and this approach has the potential to be more informative than traditional protein assays. Although validated and expanded analyses of more subjects are needed, our analyses do display remarkably different ratios of mutant/wild-type apoA-I in HDL from the two groups of heterozygotes; ratio >1 in apoA-I K131del and ratio <1 in apoA-I L202P . Possible clinical effects of these results are as yet unclear but interestingly indicate that apoA-I K131del could be more stable than the wild-type variant.
The analyses of HDL protein composition showed significantly less apoE and more zinc-α-2-glycoprotein in the apoA-I L202P heterozygotes and significantly more α-1-antitrypsin and transthyretin in the apoA-I K131del heterozygotes, compared to controls.
A reduction of apoE, another protein with atheroprotective properties [26] , may be an additional risk factor for CVD in apoA-I L202P heterozygotes. The function of zinc-α-2-glycoprotein is largely unknown but it is regarded as a novel adipokine involved in immune responses [27] . The protein has also been suggested as a biomarker for CVD as the levels are positively associated with C-reactive protein and triglyceride levels, and negatively associated with HDL-C levels in obese subjects with metabolic syndrome [28] .
Increased expression of the serine protease inhibitor α-1-antitrypsin in HDL of apoA-I K131del heterozygous carriers may reflect increased inflammation in the vascular wall since -1-antitrypsin is a well-known acute phase reactant with anti-inflammatory and immuno-modulatory properties that binds to HDL [29] . Furthermore, it may be involved in several different inflammatory diseases, including atherosclerosis [30] [31] [32] .
We also found more of transthyretin in HDL of carriers with this mutation.
Transthyretin is an abundant serum protein that can associate with HDL and LDL [33] . There is no data on a possible function of transthyretin in lipoproteins but the protein has been described as an apoA-I interacting cryptic protease that increases apoA-I amyloidogenicity [34] . In line, the apoA-I K131del mutation has been found in intimal amyloidosis deposits combined with extensive atherosclerosis [15] . Previous proteomic studies have suggested that sulfated transthyretin is a biomarker for myocardial infarction [35] while others showed an inverse correlation between transthyretin and cardiovascular risk [36] .
In our study, we have not addressed whether the mutations in apoA-I studied affect HDL cholesterol levels in plasma through anabolic or catabolic processes. Such studies of fractional synthetic and catabolic rates can be performed by gene transfer of the apoA-I mutants in apoA-I deficient backgrounds or transgenic mice of these mutants in apoA-I deficient backgrounds. However, patients suffering from complete apoA-I deficiency are characterized by pronounced HDL deficiency [37, 38] . On the other hand, overexpression of apoA-I causes increased levels of HDL cholesterol in mice. Although, we have not identified homozygotes for the L202P and K131del defects, it is safe to assume that these mutations also affect the production of small nascent HDL and that the mutated apoA-I's are likely poor substrates for lipidation by ABCA1. Of note in this regard is that ABCAI deficiency (a disorder also known as Tangier Disease) is in contrast characterized by hypercatabolism of small (abnormal) nascent HDL which also leads to HDL deficiency.
The inverse correlation between HDL-C and CVD is well established and many studies have shown that a decrease in HDL-C is associated with an increased risk of CVD. However, HDL-C levels are influenced by many factors that also influence CVD risk [5, 39] . Interestingly, Sbrana et al recently concluded that also patients with elevated HDL-C may develop CVD but later in life [40] . In addition, a recent
Mendelian Randomization study provides strong evidence that genetic mechanisms raising HDL-C do not always confer lower risk of myocardial infarction [41] . This study adds to the current confusion on the HDL hypothesis, i.e. whether HDL-C is causally related to atherosclerosis or not [42] . In the case of apoA-I, however, most studies are consistent with a loss of apoA-I being atherogenic, while an increase in apoA-I is atheroprotective [2, 5] . While the association between apoA-I mutations and risk of atherosclerosis is more complex, the current study shows that in heterozygotes we found that the mutants studied also distinctly affected the concentrations of other proteins in the HDL fraction. 
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